Peptides for inhibition of apoptosis and pharmaceutical compositions containing them
The present invention relates to an isolated and purified peptide of the RY domain having an amino acid sequence of general formula (I) comprising a sequence of the following amino acids: X 1 —X 2 —X 3 —X 4 —X 1 —X 4 —X 4 —X 3 —X 1 , X 1 =Phe, Tyr, or any amino acid having a substituted aromatic residue; X 2 =Glu, Asp, Ser, or any amino acid having a —(CH 2 ) n —COO residue, wherein n=0-3; X 3 =Asp, Thr, any aliphatic amino acid, or any of amino acids X 4 ; and X 4 =Arg, Lys, or any amino acid having a —(CH 2 ) n —NH 3 + residue, or a —(CH 2 ) n —NH—C(NH 3 + )NH 2 residue wherein n=0-4; as well as functional equivalents thereof. The invention relates also to pharmaceutical compositions comprising a compound of general formula (I), the use of said RY peptide and of said pharmaceutical composition in the preparation of a medicament and in method for the treatment of disorders of inappropriate activation of apoptosis; for increasing the number of viable cells in a biological tissue; and in a method for the enhancement for the survival of biological cells. The invention also relates to a method for the preparation of a RY-peptide of general formula (I). Furthermore, the invention also relates to an in vitro assay system for the regulation of cell death by the Bcl-2 family of test compounds (as hereinbefore defined).
1. An isolated and purified peptide of the RY domain having an amino acid sequence of general formula I comprising a sequence of the following amino acids:
x 1 —x 2 —x 3 —x 4 —x 1 —x 4 —x 4 —x 3 —x 1 I
x 1 =Phe, Tyr, or any amino acid having a substituted aromatic residue;
x 2 =Glu, Asp, Ser, or any amino acid having a —(CH 2 ) n —COO residue, wherein n=0-3;
x 3 =Asp, Thr, any aliphatic amino acid or any of amino acids X 4 ; and
x 4 =Arg, Lys, or any amino acid having a —(CH 2 ) n —NH 3 + residue, or a —(CH 2 ) n —NH—C(NH 3 + )NH 2 residue wherein n=0-4.
2. A peptide according to claim 1 , wherein Methionine (Met) is connected to the N-terminal of the sequence of general formula L.
3. A peptide according to claim 1 or 2 wherein in the sequence of general formula I, the sequence is X 4 —X 1 —X 4 —X 4 stands for Arg-Tyr-Arg-Arg.
4. A peptide according to claim 3 , wherein the sequence is preceded by X 3 =Arg.
5. A peptide according to claim 1 , wherein the substituted aromatic residue of X 1 is Phenyl —(CH 2 ) n —.
6. A peptide according to claim 1 , wherein the aliphatic amino acid of X 3 is selected among Leu, Ile, Ala, Gly and Val.
7. Phe-GIu-Leu-Arg-Tyr-Arg-Arg-AIa-Phe.
8. Phe-Ser-Arg-Arg-Tyr-Arg-Arg-Asp-Phe.
9. Phe-Glu-Thr-Arg-Phe-Arg-Mg-Thr-Phe.
10. A pharmaceutical composition comprising as active ingredient a RY peptide according claim 1 .
11. A pharmaceutically composition according to claim 10 , comprising a pharmaceutically acceptable carrier.
12. A method for the treatment of disorders of inappropriate activation of apoptosis comprising the step of administering a pharmaceutical composition according to claim 10 to a subject in need thereof.
13. A method for increasing the number of viable cells in a biological tissue comprising the step of administering a pharmaceutical composition according to claim 10 to a subject in need thereof.
14. A method for the enhancement for the survival of biological cells comprising the step of administering a pharmaceutical composition according claim 10 to a subject in need thereof.